Jeffrey W. Albers, Director at Blueprint Medicines Corp (BPMC), sold 44,000 shares at $50.17 ($2.2M) on 2023-09-28, disclosed to the SEC on 2023-09-29.
Scheduled sale ($2.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $48.84 | 5,600 | $274K | 12.5% |
| 2 | $49.93 | 12,102 | $604K | 27.5% |
| 3 | $49.93 | 12,102 | $604K | 27.5% |
| 4 | $50.50 | 400 | $20K | 0.9% |
| 5 | $50.17 | 6,898 | $346K | 15.8% |
| 6 | $50.17 | 6,898 |
| $346K |
| 15.8% |
| Total | $49.87 avg | 44,000 | $2.2M | 100% |
| Filing → |
| KYMR | SELL | 2025-10-14 | $296K | — | Filing → |
| KYMR | SELL | 2025-06-03 | $311K | — | Filing → |
| BPMC | SELL | 2025-05-29 | $572K | — | Filing → |